The Research Innovation Group (RIG) manages the intellectual property portfolio and industry contracting activities for Saint Louis University.
RIG’s mission is to increase the adoption and dissemination of SLU research discoveries and intellectual properties and to leverage SLU research and innovation assets to benefit the community. Our goal is to become exceptional at technology transfer and industry engagement as well as a partner of choice for research and intellectual property commercialization.
RIG’s main office is located in the heart of the Cortex Innovation Community to better connect with industry and integrate SLU within the region’s innovation and entrepreneurship ecosystem. The Cortex Innovation Community was founded in 2002 through a collaboration among SLU, Washington University in Saint Louis, University of Missouri – St. Louis, BJC Healthcare, and the Missouri Botanical Garden. It is the Midwest’s premier innovation hub for research, development, and commercialization in biosciences and technology. Cortex anchors the St. Louis region’s growing innovation ecosystem for startups and established companies.
The Research Innovation Group at Saint Louis University strives to be fast, efficient, and helpful when serving community members. Let us know how we can best support you as you go pursue Truth. Please don't hesitate to contact us if you need further assistance.
- Understand my obligations to disclose inventions and innovations
- Determine what type of agreement I need
- Download intellectual property disclosure form
- Download material transfer agreement (MTA) intake form
- Download license agreement distribution form
- Learn about the technology transfer process
- Learn about the various options for increasing the dissemination and adoption of my research discoveries.
The Research Innovation Group at Saint Louis University offers support and encouragement to student entrepreneurship, innovation, and research excellence in a variety of ways. All current students are very welcome to contact us if you have any questions.
- Learn about graduate student obligations to disclose intellectual property
- Find out if I have an obligation to disclose intellectual property as an undergraduate student
- Inquire about student worker positions with the Research Innovation Group
- Learn about the Chaifetz Center for Entrepreneurship
- Learn about entrepreneurship degree programs in the Chaifetz School of Business
MEDLaunch is a non-profit biomedical and entrepreneurship incubator partnering with Saint Louis University and other organizations in the Saint Louis area. The goal of MedLaunch is to improve the standard of healthcare through the engineering and design of creative solutions while also fostering a community of entrepreneurship and collaboration at Saint Louis University.
The Research Innovation Group at Saint Louis University is committed to leveraging our research and innovation assets for the benefit of our community. We strive to generate real impact in tackling social and scientific challenges facing our society through partnerships and programs.
The September 2017 Reinventing Research Commercialization Conference
The Research Innovation Group is committed to developing and implementing new approaches to technology transfer. It knows these will be needed to bring transformative discoveries resulting from university research more quickly and effectively to market. To this end, in September 2017, the Research Innovation Group brought together national leaders in technology transfer, regional innovators, entrepreneurs, business managers and advisors at the "Reinventing Research Commercialization Conference" to participate in this reinvention process.
The presentations from this conference are available below.
- "The Academic Venture Exchange," Alan Thomas
- "Commercialization Successes and Challenges," Jed Taylor
- "Saint Louis University: Five Year Research Growth Plan," Ken Olliff
- "Reinventing Research Commercialization," Georgia Tech
- "Advancing Entrepreneurship, Innovation and Technology Transfer," Sethuraman Panchanathan
- "Technology Entrepreneurship Center," Engineering at Illinois
- "Developing and Growing University Based Startups," Rosemarie Truman
Saint Louis University strives to be a partner of choice for university research and intellectual property commercialization. Please contact us if you would like to discuss specific technologies or other opportunities to collaborate with us.
- License a SLU intellectual property
- Sponsor research at Saint Louis University
- Collaborate with SLU on a clinical trial
- Learn about fee-based services offered to industry by SLU faculty
- Sponsor a student thesis project focused on a specific issue or opportunity
- Explore the capabilities of the Bioinformatics Laboratory
- Explore the capabilities of the Genomics Core Facility
- Explore the capabilities of the Protein Core Facility
Technology Transfer Fellows Program
The Technology Transfer Fellows Program aims to help individuals develop translational research and lean innovation skills through experiential learning; expose individuals, particularly those from underrepresented groups, to the field of technology transfer; and facilitate the dissemination and adoption of Saint Louis University research discoveries and technologies.
Participants in the program can earn an award up to $1,000 per project while working to advance the transfer of Saint Louis University technologies to the private sector to benefit the public interest.
Individuals interested in participating in the Technology Transfer Fellows Program may apply online at any time. The program is operated by the Research Innovation Group within the Office of the Vice President for Research at Saint Louis University. Please contact Malcolm Townes by phone at 314-977-1633 or by email at email@example.com if you have any questions.
Anyone who meets the following requirements can participate in the Technology Transfer Fellows Program:
- Individuals at least 18 years of age.
- Eligible to work in the United States (if not a student or employee of Saint Louis University).
Participation in the program is at the sole and absolute discretion of Saint Louis
University. In addition to faculty, staff, postdoctoral researchers, graduate students,
and undergraduate students at Saint Louis University, non-SLU affiliated individuals
may also participate in the program.
Participation in the Technology Transfer Fellows Program is not meant to replace a person's current employment. Individuals are expected to participate in the program in adjunct to their normal jobs.
Technology Transfer Fellows participate in the SLUStart I-Corps program to advance the transfer of specific Saint Louis University technologies to the private sector to benefit the public interest. This includes completing at least 10 customer discovery interviews and documenting a venture thesis for a technology. The primary tasks are as follows:
- Task 1: Participate in an initial SLUStart I-Corps cohort working session.
- Task 2: Participate in a second SLUStart I-Corps cohort working session.
- Task 3: Prepare a plan for recruiting individuals for customer discovery interviews.
- For enterprise applications, provide a profile of the target user and a preliminary list of appropriate individuals (including job titles, company affiliation, and contact information) that the participant will approach for customer discovery interviews.
- For consumer applications, provide a profile of the target user and a summary of the approach for contacting individuals in the target segment.
- Task 4: Complete and document the first five (5) customer discovery interviews according to program standards.
- Task 5: Complete and document the next five (5) customer discovery interviews according to program standards and submit a venture thesis.
For individuals who are outside of the St. Louis, Missouri area, we can make special arrangements if necessary to facilitate their participation in the SLUStart I-Corps cohort sessions (i.e., Task 1 and Task 2).
With approval from the program manager, Technology Transfer Fellows can work on any technology for which Saint Louis University has received an intellectual property disclosure that is not less than 60 days old, has accepted assignment of the technology, and is actively pursuing commercialization.
Fellows may work on multiple projects during their participation only if invited to do so. However, they may only work on one project at a time. Once a participant completes a project, the program manager will evaluate the participants work and deliverables. If the deliverables are satisfactory, the program manager may invite the fellow to perform additional work on the project or work on a different project.
Fellows may work on projects either individually or in teams of two with the approval of the program manager.
Technology Transfer Fellows earn an award up to $1,000 per project. The award is per individual. Each fellow working on a project as a part of a team may earn an award up to $1,000 for achieving project milestones. The award accrues based on project milestone attainment. The current award accrual schedule per project is as follows:
- Deliverable 1: Documentation of participation in the first SLUStart I-Corps cohort session: $100.00
- Deliverable 2: Documentation of participation in a second SLUStart I-Corps cohort session: $100.00
- Deliverable 3: Documentation of a plan for recruiting individuals for customer discovery
interviews according to program standards: $150.00
- For enterprise applications, provide a profile of the target user and a preliminary list of individuals (including job titles, company affiliation, email, and telephone number) that the participant will approach for customer discovery interviews.
- For consumer applications, provide a profile of the target user and a summary of the approach for contacting individuals in the target segment.
- Deliverable 4: Documentation of the first five (5) customer discovery interviews and an initial venture thesis statement according to program standards: $325.00
- Deliverable 5: Documentation of the next five (5) customer discovery interviews and venture thesis statement according to program standards : $325.00
Fellows have a limited amount of time to complete a project (typically about 2 months). Awards payments are distributed after completion of all deliverables or expiration of the time allotted for the project, whichever occurs first.
The two working sessions (i.e., SLUStart I-Corps cohort sessions) typically last about
three (3) to four (4) hours each. The meeting days and times for the cohort working
sessions are scheduled according the availability of the cohort participants. In
many cases, cohort sessions are scheduled on weekends or weekday evenings for the
convenience of participants.
Additionally, Fellows are expected to spend time outside of the working sessions applying what they've learned to conduct customer discovery interviews for their assigned SLU technologies. However, exactly how much time a participant spends outside of the working sessions is at their discretion and will vary from project to project. The amount of time it takes to conduct each customer discovery interview is typically about 30 minutes but this varies to some degree. This does not include the time required to recruit and schedule an interview participant.
Search Intellectual Property Portfolio
Use the directory below to browse and search our intellectual property portfolio to identify technologies that may be of interest to you.
|98-013||NK3.3 Human Natural Killer Cell Line Derived from Healthy Male||Research Tool|
|03-016||Studying Oncolytic Adenovirus Vectors Using a Syrian Hamster Model||Research Tool|
|03-017||Studying Oncolytic Adenovirus Vectors Using a Cotton Rat Model||Research Tool|
|06-013||Treating Metabolic Disorders in a Fetus||Therapeutic|
|06-047||Treating Immune System Mediated Diseases Using TAT-BH3||Therapeutic|
|07-023||Minimizing Risks and Complications Associated with Retinal Detachment Surgery||Medical Device|
|10-001||Improving Weather-Influenced Decisions Using Environmental Predictive Analytics||Industrial Application|
|10-010||Developing an Antiviral Vaccine for Herpes Simplex Virus by Encoding Co-stimulation Molecules||Therapeutic|
|10-014||Improving Robotic Systems for Brain Surgery Using a Self-Opening Distractor||Medical Device|
|10-015||Improving Operating Room Procedures Using a Finger-based Data Input Device||Medical Device|
|10-017||Detecting DNA and RNA Using Biolayer Interferometry with Ultra-High Sensitivity||Diagnostic|
|10-018||Preventing and Treating Influenza Using Peptides to Induce Heterosubtypic Influenza T Cell Responses||Therapeutic|
|10-019||Assessing the Language Proficiency of Individuals Using Crowdsourced Examinations||Industrial Application|
|11-010||Studying Chronic Liver Disease Using a PiZ Transgenic Mouse Model of a1At Mutant Z Liver Injury||Research Tool|
|11-013||Testing for Inherited Metabolic Diseases||Diagnostic|
|11-015||Novel Approach for Treating Cancer Using Adenovirus E1A Fragments||Drug Delivery|
|11-027||Treating Cornelia de Lange Syndrome Using Indomethacin-based Drugs||Therapeutic|
|12-013||Preventing Bone Loss by Regulating FOXP3+CD8 T Cells||Therapeutic|
|12-014||Treating Malaria Using Aminohydantoin Compounds||Therapeutic|
|13-014||Microfluidic Device Systems and Methods for Fabrication||Industrial Application|
|13-020||Treating Chronic Neuropathic Pain Using Phenotypic Screening||Therapeutic|
|14-013||Delivering Bioactive Components Using a Hydrolytically Degradable Polyethylene Glycol Microsphere||Drug Delivery|
|14-017||Diagnosing and Treating Endometriosis-related Infertility||Therapeutic|
|14-018||Novel Therapeutic Strategy for Treating Human Breast Cancer Regulating SALL1 Functions||Therapeutic|
|15-012||Producting Biomaterial Platforms for Researching Cell Substrate Relationships||Industrial Application|
|15-014||Treating Cancers, Neurodegenerative Diseases, and Other Rare Conditions Using MUB LBL and LBL-based Peptides||Drug Delivery|
|15-015||Suppressing Tumors Using MCPIP1||Therapeutic|
|15-026||Improve Tissue Healing Using a Honey-eluting Cryogel for Tissue Engineering||Drug Delivery|
|15-027||Producing a Biocompatible and Biodegradable Silk Fibroin Cryogel for Use in Tissue Engineering||Drug Delivery|
|15-032||Promoting Nerve Repair Using Neural Tissue Engineering Method of Transferring Single-Walled Carbon Nanotubes on a Hydrogel||Drug Delivery|
|16-006||Integrating 3-Dimensional Cell Culture Scaffolds in Microfluidic Devices||Industrial Application|
|16-011||Preventing and Treating Infections Caused by Herpesviridae Using Mutant Herpes Simplex Virus||Therapeutic|
|16-018||Producing Nanomaterials Using Mask-free Production Methods||Industrial Application|
|16-025||Blue Fluorescent Molecules for Organic Light Emitting Diodes||Industrial Application|
|17-002||Novel Antibiotic Candidates Based on Inhibitors of Nucleotidyltransferase Superfamily Enzymes||Therapeutic|
|17-003||Deriving Photoinduced Ring Closure From Dinaphthothiphenes||Industrial Application|
|17-004||Treating Cancers and Infectious Diseases Using NK3.3-Derived Extracellular Vesicles||Therapeutic|
|17-007||Measuring GPER Agonism, Antagonism, and Inverse Agonism Using a Novel High-Throughput Screening Assay||Diagnostic|
|17-008||Maintaining GALNS Enzyme Activity for Extended Periods Using an Injectable Hydrogel Depot||Drug Delivery|
|17-010||Regenerating Tissue Using an Aligned Electrospun Matrix of Decellularized Muscle||Therapeutic|
|17-013||Treating Atherosclerosis by Induction of TcREG||Therapeutic|
|17-015||Treating Short Gut Syndrome and Preventing Necrotizing Enterocolitis Using Fatty Acid Conjugated Epidermal Growth Factor Variants||Therapeutic|
|17-017||Treating Facioscapulohumeral Muscular Dystrophy (FSHD) Using P38 Inhibitors||Therapeutic|
|17-018||Minimizing the Collection Time for Hematopoietic Stem Cells Using Novel VLA4 Antagonist Compounds||Drug Delivery|
|17-019||Minimizing the Collection Time for Hematopoietic Stem Cells Using Novel VLA4 Antagonist Compounds||Drug Delivery|
|17-024||Measuring the Efficiency of Efflux Pumps in Bacterial Strains and Permeability Properties of Bacterial Cell Envelopes Using a Molecular Fluorescent Ruler||Diagnostic|
|17-025||Repairing and Regenerating Tissue Using Biomimetic Sponges||Therapeutic|
|17-026||Treating Muscle Dysfunction Using ERR Ligands||Therapeutic|
|17-033||Treating Malaria Using Pyrrolidine Compounds||Therapeutic|
|17-034||Assessing Biofilm Infections Using a Novel Bacterial Biofilm Assay||Diagnostic|
|17-036||Treating Malaria Using Pyrrolidine Compounds||Therapeutic|
|17-037||Dibenzothiophene Sulfone Cell Dyes||Research Tool|
|17-038||Detecting Hemoglobin C in Environments that Lack Modern Infrastructure Using a Method Based on Induction of Intracellular HbC Crystals||Diagnostic|
|17-039||Treating Cancer Using Novel Molecules for Photodynamic Therapy||Drug Delivery|
|17-040||Improving Cognitive Function in Aging-related Dementia Using Adropun Peptides||Therapeutic|
|17-041||Treating Atherosclerosis by Induction of Regulatory CD8T Cells||Therapeutic|
|18-003||Treating Cancer Using Synthesis of a Molecule that Undergoes S-O Bond Cleavage to Produce a Toxic Compound||Therapeutic|
|18-006||Performing Multiple PCR-based Laboratory Developed Tests Simultaneously Using a Common PCR Platform System||Research Tool|
|18-010||Studying the Role of GPER in Various Diseases Using Novel GPER Agonists||Research Tool|
|18-012||Developing Better Treatments for Resistant Cancers Using Novel Small Molecule Inhibitors of the Human RECQ1 Helicase||Drug Delivery|
|18-013||Eliminating Bacterial Biofilms Using a Phytochemical||Therapeutic|
|18-017||Treating Facioscapulohumeral Muscular Dystrophy (FSHD) Using P38 Beta-selective Inhibitors||Therapeutic|
|18-018||Developing Treatments for Hematological Disorders Caused by B19V Infection Using Small Molecule Compounds That Directly Inhibit B19V Replication||Drug Delivery|
|18-020||Treating Zika Virus Using Selective Estrogen Modulators||Therapeutic|
|18-023||Treating Facioscapulohumeral Muscular Dystrophy (FSHD) Using Pyrrolopyridinone Compounds that Inhibit BET Bromodomains||Therapeutic|
|18-024||Improving the Consistency of Image-guided Head and Neck Radiotherapy Delivery Using an Auto-adaptable Head Rest||Medical Device|
|18-026||Generating Atomic Oxygen Using Visible Light||Drug Delivery|
|18-027||Treating Hepatitis B Virus Infection Using Alpha-Hydroxytropolones as Inhibitors of HBV Replication||Therapeutic|
|18-028||Improving Large-Scale Study of Proteins Using Mass Spectroscopy with Isotope Labeling||Research Tool|
|19-001||Creating New Fluorescent Microscopy Plasma Membrane Dyes Using DBTOO Analogs||Research Tool|
|19-006||Automating the Analysis of Chimerism Data||Research Tool|
|19-007||Detecting Exposure to Specific Pathogens and Agents||Diagnostic|
|19-008||Minimizing Epidural Catheter Migration||Medical Device|
|19-009||Treating Fungal Infections in HIV-positive Patients and Solid Organ Transplant Recipients||Therapeutic|
|19-010||Improving Tumor Immunotherapy by Reprogramming Lipid Metabolism||Therapeutic|
|19-011||Delivering Medicines in a Controlled Manner Over an Extended Period of Time Using Degradable Hydrogels||Drug Delivery|
|19-012||Custom Plasmids for Expressing Nuclear Receptor Proteins in E. Coli and Optimized Protocols for Protein Expression and Purification||Therapeutic|
|19-013||Introducing Tangible Interactions into Existing Telepresence and Telerobotics Systems||Medical Device|
|19-014||Using GCNF Ligands to Increase the Efficacy of Cancer Therapeutics||Therapeutic|
|19-015||Using a Novel Mechanism to Treat MRSA Infections and Tuberculosis||Therapeutic|
|19-016||Video and Microphone Enabled Keypad for Use in Healthcare Systems||Medical Device|
|19-017||Improving Telepathology||Medical Device|
|19-018||Locating and Quantifying Off-Target Embolization||Diagnostic|
|19-019||Treating and Preventing Neuropathic Pain Using Novel Non-Narcotic Analgesics||Therapeutic|
|19-020||Treating Neurological Diseases, Autoimmune Disorders, and Muscular Disorders Using Rev-erb Modulators||Therapeutic|
|19-021||Improving the X-Ray Imaging of the Vasculature of Biological Systems||Diagnostic|
|19-022||Improving Tissue Engineering Scaffolds for Wound Healing Using Metallic Nanoparticles||Medical Device|
|19-024||Simplifying Polyaxial Screw Insertion During Robotic Spinal Surgery||Medical Device|
|19-025||Preventing Herpes Simplex Virus Replication with a New Class of Drugs that Act by a Novel Mechanism||Therapeutic|
|19-027||Treating Frontotemporal Dementia||Therapeutic|
|19-028||Improving DNA Sequencing||Diagnostics|
|19-029||Treating Traumatic Brain Injuries||Therapeutic|